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by Michael J. Parnell,* Loren D. Koller,* Jerry H. Exon,*
and Jeanene M. Arnzen*
The initiating and promoting effects oftrichloroacetic acid (TCA) were investigated using a rat hepatic
enzyme-altered foci bioassay. The experimental protocol used has been shown to induce y-glutamyltrans-
peptidase (GGT)-positive foci in hepatic tissue following an initiating dose with a genotoxic carcinogen.
Twenty-four hours following % partial hepatectomy, rats received eithera single oral dose (1500 mg/kg) or
5000 ppm TCA in drinking water for 10, 20, or 30 days. Two weeks after the end ofTCA exposure, the rats
were promoted for 3 or 6 months with 500 ppm phenobarbital in drinking water. TCA failed to induce
GGT-positive foci using this initiation protocol.
In addition, groups of% partially hepatectomized rats were initiated with a single oral dose ofdiethyl-
nitrosamine (10 mg/kg) and then administered 50, 500, or 5000 ppm TCA drinking water. In this promotion
protocol, TCA exposure resulted in a significant increase in the number of GGT-positive foci.
The ability of TCA to stimulate peroxisomal-dependent palmitoyl-coenzyme A oxidation was also in-
vestigated. Only the 5000 ppm TCA treatment within the promotion protocol resulted in a significant,
although minor, stimulation of peroxisomal enzyme activity.
The findings support the hypothesis that TCA may possess weak promoting activity in the rat liver.
Introduction
The presence of trichloroacetic acid and other non-
volatile halogenated organic products of water chlori-
nation in drinking water has only been recently rec-
ognized (1-6). Consequently, very few data are
available concerning expected environmental levels or
what, if any, adverse effects these chemical products
may have on biological systems.
Trichloroacetic acid (TCA), dichloroacetic acid
(DCA), and chloral hydrate aremajor nonvolatile chlor-
inated products formed during chlorination of water
containing organic material (1-5). What few data are
available concerning levels of these compounds in fin-
ished drinkingwaterindicate thattheirconsistent pres-
ence ranges from ten to several hundred parts per bil-
lion (2,3). The environmental levels ofthese nonvolatile
chlorination products will certainly vary with local con-
ditions and are directly related to the concentration of
humicmaterials present inthe water(3,5). Enteric pro-
duction ofTCA and DCA following oral administration
ofsodium hypochlorite has also been demonstrated (7).
Although TCA and DCA are structurally similar, chlo-
rination studies of fulvic and humic acids indicate that
TCA formation does not proceed through a DCA inter-
mediate, but that both formindependently (3). The rel-
ative concentration ofeach depends onthereaction con-
ditions (3,6).
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PurifiedTCAandDCAarenonmutagenicintheAmes
assay (8-10), although some ofthe nonvolatile by-prod-
ucts formed during water chlorination do exhibit mu-
tagenic activity in the Ames assay (2).
TCA is also used as a pre-emergence herbicide, med-
ically as a caustic agent for chemical cautery, and as a
common laboratory reagent. These direct uses ofTCA
are not, however, considered major sources ofenviron-
mental contamination and exposure.
DCA has direct uses in agriculture as a fungicide and
issimilarlyclassifiedtoxicologicallyasacorrosive. How-
ever, duringthe last decade, DCAhasbeenextensively
investigated for potential therapeutic use as a hypo-
glycemic, hypolactatemic, andhypolipodemicagent(10-
14). It has been used to treat diabetes mellitus, lactic
acidosis, and hypercholestrolemia in man, but because
of its toxicity at therapeutic doses, clinical trials have
been halted (10,14). Although DCA exerts various met-
abolic effects on many tissues, its hepatic effects are
the most prominent (11,12). DCA has also been shown
to be a metabolite of various hepatotoxic organochlo-
rines such as dichloroethylene, dichloroethane (a he-
patic carcinogen in rats), and tetrachloroethane (a he-
patic carcinogen in mice) (15-18). These halogenated
organics are commonly found as pollutants in surface
water and groundwater supplies (19-22).
TCA is metabolically related to trichloroethylene
(TCE), an organic solvent with wide industrial appli-
cation and a contaminant ofsurface water and ground-PARNELL ET AL.
water (19,22). TCA, and trichloroethanol are the major
animalandhumanmetabolites ofTCE (23-26). Initially,
TCE is oxidized to chloral hydrate, which is either re-
duced to trichloroethanol or oxidized to TCA. Biotrans-
formation ofchloral hydrate results in the formation of
the same metabolites. Lifelong, high-dose, oral expo-
sure to TCE has produced hepatocellular carcinomas in
mice, but not in rats (27,28). More recently, oral admin-
istration of TCE has been shown to stimulate hepatic
peroxisomal proliferation in mice, but not in rats. How-
ever, oral administration of TCA induces hepatic per-
oxisomal proliferation in both species (29,30).
Compounds that are known to induce hepatic per-
oxisomal proliferation in rodents are a chemically di-
verse group that includes hypolipodemic agents and in-
dustrial plasticizers. Several of these peroxisomal
proliferators have been reported to produce liver tu-
mors in rats and mice (31-33). These same compounds
fail to exhibit mutagenicity in the Ames assay (31,34).
Recent kinetic studies in TCE-exposed rats and mice
indicate that the increased blood levels ofTCA in mice
compared to rats may explain the greater susceptibility
of mice to TCE-elicited hepatocellular carcinomas
(24,25,30).
The nearly universal practice ofdrinking water chlo-
rination ensures widespread, low-level, chronic envi-
ronmental exposure to TCA and DCA. When combined
with enteric formation from chlorine ingestion and pos-
siblehalogenated organic watercontamination, thelike-
lihood of significant human exposure and possible toxic
effects is increased.
The numerous hepatic effects ofTCA and DCA sug-
gest the liver as a probable target organ. Further, the
metabolic relationship of TCA to TCE, a hepatic car-
cinogen, and of DCA to other chlorinated organic he-
patic toxicants and carcinogens, makes the assessment
of hepatic carcinogenic potential of both compounds a
rational objective.
The object ofthis study was to evaluate the initiating
and promoting activity of TCA using a rat liver foci
bioassay. The putative preneoplastic enzyme-altered
foci were identified by histochemical staining for y-glu-
tamyltranspeptidase (GGT) activity. Possible hepatic
peroxisomal stimulating effects were also investigated.
Materials
Male Sprague-Dawley rats (Washington State Uni-
versity, Pullman WA), 5 to 6 weeks old, were housed
ingroups offourin stainless-steel, wire-bottomed cages
under controlled conditions of temperature, humidity,
and lighting. These were given free access to Labora-
tory Chow (Ralston Purina Co., St. Louis, MO) and
deionized drinking water.
Diethylnitrosamine (DEN), reagent grade, was pur-
chased from Sigma Chemical Co. (St. Louis, MO); so-
dium phenobarbital (PB) and sodium hydroxide, re-
agent grade, were purchased fromJ.T. Baker Chemical
Co. (Phillipsburg, NJ); [1-14C]palmitoyl-CoA was pur-
chased from New England Nuclear Products (Boston,
MA); N-L-glutamyl-4-methoxy-2-naphthylamine was
purchased from Polysciences (Warrington, PA); and
TCA, 99+% reagent grade, was purchased from Ald-
rich Chemical Co. (Milwaukee, WI). Other reagents
were purchased from Sigma Chemical Co. or VWR Sci-
entific (Seattle, WA).
Methods
Figure 1 and Table 1 illustratethedesignandprotocol
oftheinitiationstudy. Briefly,animalsunderwent%par-
tial hepatectomy (35) or sham operation (group G) fol-
lowed24hrlaterbysingle-dose, oralgavagewith DEN,
10 mg/kg (group A), or TCA, 1500 mg/kg (group B).
The remaining groups were administered TCA at 5000
ppm in their drinking water for 10, 20, or 30 days. Two
weeks following the initiation period, all groups were
administered PB (500 ppm) in drinking water for the
remainder of the study. Animals were randomly sam-
pled 24 hr after the end of initiation, 24 hr before the
start ofpromotion, and at the 3- and 6-month intervals
ofthe promotion period.
Figure2andTable2illustratethe designandprotocol
of the promotion study. Similarly, animals were sub-
jected to partial hepatectomy (PH) or sham operation
(group Q), followed 24 hr later by oral gavage with
either DEN at 10 mg/kg body weight or distilled water
(groups Q and R). Two weeks later, 500 ppm PB or
TCA at 50, 500, or5000ppmwere added tothe drinking
water for all groups except Group R. Animals were
randomly sampled at 2-week, 1-month, 3-month, and 6-
month intervals.
To prepare the TCA-containing drinking water,
enough TCA was added to deionized water to make the
5000 ppmconcentration. This mixture was thentitrated
to a pH of 6.5 to 8.0 using reagent-grade sodium hy-
droxide. Tenfold dilutions ofthis original mixture were
used to obtain the 500 ppm and 50 ppm TCA concen-
trations.
2 -..... initiation period .... . promotion period1
._- 24 hours -- 1, 10, 20, or 30 days -_ 2 weeks * _ 3 mo 6mo
PH DEN S' So PB Sob Sb
TCA
FIGURE 1. Experimental design ofenzyme-altered hepatic foci test for initiating activity. PH = partial hepatectomy, DEN = diethylnitro-
samine, PB = sodium phenobarbital, and S = sampling interval. a denotes peroxisomal-associated palymitoyl-CoA oxidation assay; b
denotes body/organ weights and GGT-positive foci assay.
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Table 1. Experimental initiation protocol.a
Group A Group B Group C Group D Group E Group F Group G
PH + + + + + - +
Initiator DEN TCA (gavage) TCA TCA TCA TCA
Days dosed 1 1 10 20 30 30
Promotor PB PB PB PB PB PB PB
'DEN was administered in a single oral gavage dose, 10 mg/kg in distilled water; TCA was administered in a single oral gavage dose, 1500
mg/kg in distilled water (noted as TCA in gavage) or was administered in drinking water, 5000 ppm. PB was administered in drinking water
500 ppm.
-- -- -- promotion period - .-----
Il I I I
_- 24 hours _m|- 2 weeks _12 weeks 1 mo 3 mo 6 mo
PH DEN PB S. S SO SO
(Initiation)
FIGURE 2. Experimental design ofenzyme-altered hepatic foci test
for promoting activity. PH = partial hepatectomy, DEN = di-
ethylnitrosamine, PB = sodium phenobarbital, and S = sampling
interval. a denotes peroxisomal-associated palmitoyl-CoA oxida-
tion assay; b denotes body/organ weights and GGT-positive foci
assay.
Quantification of GGT-positive Foci
y-Glutamyltranspeptidase was detected according to
the method ofRutenberg etal. (36). Fresh liversections
were collected at the 3- and 6-month sampling periods
ofboth the initiation and promotion protocols, frozen in
liquid nitrogen, and stored at -70°C until used.
Sections (5um) were cut on a cryostat, placed on a
slide, airdried, fixed in cold absolute ethanolfor30min,
stained for GGT activity, and counterstained with he-
matoxylin. GGT-positive foci containing nine or more
nuclei were counted directly from the prepared slide
using a digitizing pad coupled optically to a microscope.
At least 3 cm2 ofliver were assessed from each animal.
Foci/cm2 was evaluated for each animal by dividing the
total number of foci present by the total area of liver
assessed.
Peroxisomal 13-Oxidation Assay
Fresh liver samples were collected at all sampling
periods, frozen in liquid nitrogen, and stored at -70°C
until used. Liver samples were thawed, weighed, and
homogenized in 10 volumes of 0.25 M sucrose using a
Brinkmann Polytron Homogenizer (3-15 sec bursts at
high speed). The ability of the homogenates to oxidize
palmitoyl-coenzyme A (CoA) was measured directly by
the oxidation of [1-14C]palmitoyl-CoA according to the
method of Lazarow (37).
Statistics
All values are expressed as the mean standard
error ofthe least squares mean. Statistical significance
was determined by analysis of variance and least
squares mean multiple comparisons. An ax level of p <
0.05 was considered to be a significant difference be-
tween groups.
Results
Peroxisomal ,3-Oxidation
TCA induced a significant (p < 0.05) and consistent
increase in peroxisomal-specific palmitoyl-CoA oxida-
tion only in the high-dose (5000 ppm) groups, P and Q,
in the promotion protocol (Table 3). The magnitude of
the increase over controls (R and S), 10 to 20%, is small
compared to those increases associated with the "typ-
ical" peroxisomal proliferators. Clofibrate, fenofibrate,
and other known hepatic peroxisomal proliferators in-
duce a 6- to 15-fold increase in peroxisomal-associated
palmitoyl-CoA oxidation (38-40). A significant (p <
0.05) depression of palmitoyl-CoA oxidation was also
evident at all sampling periods for the positive control
(group M) and appeared to be related to PB treatment.
No significant stimulation ofpalmitoyl-CoA oxidation
was seen at any ofthe sampling intervals for the TCA-
treated initiation groups (Table 4).
Organ and Body Weights
No significant increasein liverweight ofTCA-treated
rats, compared to controls, was observed at any ofthe
sampling times in either the initiation or promotion
groups (Tables 5 and 6). This lack of effect on liver
weight is compatible with the minor peroxisomal-as-
sociated palmitoyl-CoA stimulating effects produced by
high-dose TCA. Hepatomegaly has been shown to ac-
company the large increases in peroxisomal enzyme ac-
tivity associated with known hepatic peroxisomal in-
Table 2. Experimental promotion protocol.a
Group M Group N Group 0 Group P Group Q Group R Group S
PH + + + + - + +
Initiator DEN DEN DEN DEN - DEN
Promotor PB TCA (low) TCA TCA (high) TCA (high)
'DEN was administered in a single oral gavage, 10 mg/kg in distilled water; PB was administered in drinking water, 500 ppm; TCA was
administered in drinking water, 50 ppm (noted as TCA low), 500 ppm, or 5000 ppm (noted as TCA high).
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Table 3. TCA promotion C'4-palmitoyl-CoA oxidation.
Palmitoyl CoA enzyme activity, ,um/min/g livera
Group Treatment N 2 weeks 1 month 3 months 6 months
M PH/DEN/PB 6 0.37 ± 0.01* 0.36 ± 0.02* 0.45 ± 0.04* 0.54 ± 0.02*
N Ph/DEN/50 ppm TCA 6 0.49 ± 0.02 0.53 ± 0.02 0.59 ± 0.03 0.67 ± 0.02
O PH/DEN/500 ppm TCA 6 0.55 ± 0.01 0.49 ± 0.01 0.58 ± 0.01 0.64 ± 0.02
P PH/DEN/5000 ppm TCA 6 0.61 ± 0.01t 0.64 ± 0.01t 0.70 ± 0.02t 0.76 ± 0.02t
Q 5000 ppm TCA 6 0.59 ± 0.02t 0.63 ± 0.01t 0.66 ± 0.02t 0.77 ± 0.02t
R PH 4 0.52 ± 0.01 0.53 ± 0.01 0.58 ± 0.02 0.66 ± 0.02
S PH/DEN 4 0.56 ± 0.02 0.51 ± 0.02 0.62 ± 0.01 0.68 ± 0.02
aValues are expresed as means ± standard error of the least-squares mean.
*Significantly lower than groups N, 0, P, Q, R, and S by least-squares means comparisons (p
- 0.05).
tSignificantly greater than groups M, N, 0, R, and S by least-squares means comparisons (p S 0.05). All other comparisons were not
significant.
Table 4. TCA initiation C14_palmitoyl-CoA oxidation.
Palmitoyl CoA enzyme activity, ,um/min/g livera
Group Treatment N First Second 3 months 6 months
A PH/DEN/PB 6 0.49 t 0.03 0.50 ± 0.02 0.40 ± 0.01 0.57 ± 0.02
B PH/1 dose/PB 6 0.59 t 0.04 0.44 ± 0.03 0.42 ± 0.02 0.55 ± 0.02
C PH/10 days/PB 6 0.54 ± 0.02 0.57 t 0.08 0.42 ± 0.02 0.58 + 0.02
D PH/20 days/PB 6 0.55 ± 0.03 0.48 ± 0.01 0.43 ± 0.03 0.55 ± 0.02
E PH/30 days/PB 6 0.59 t 0.03 0.48 ± 0.01 0.37 ± 0.03 0.55 ± 0.02
F 30 days/PB 6 0.57 ± 0.02 0.48 t 0.01 0.37 ± 0.03 0.59 ± 0.02
G PH/PB 4 0.55 ± 0.01 0.58 ± 0.05 0.45 ± 0.01 0.57 ± 0.02
aValues are expressed as means + standard error of the least-squares mean. Significant differences are not present between groups by
least-squares means comparisons (p S 0.05).
Table 5. TCA initiation/body weights.
Organ weight as % body weighta
3 months 6 months
Group Treatment N Spleen Liver Kidney Spleen Liver Kidney
A PH/DEN/PB 6 0.22 ± 0.15 5.20 ± 0.22 0.43 ± 0.02 0.19 ± 0.01 5.20 ± 0.16 0.43 ± 0.02
B PH/1 dose/PB 6 0.22 ± 0.15 5.70 ± 0.22 0.44 ± 0.02 0.19 ± 0.01 5.17 ± 0.16 0.40 ± 0.02
C PH/10 days/PB 6 0.22 ± 0.15 5.96 ± 0.22 0.52 ± 0.02 0.20 ± 0.01 5.04 ± 0.16 0.41 + 0.02
D PH/20 days/PB 6 0.26 ± 0.15 5.51 ± 0.22 0.50 ± 0.02 0.20 ± 0.01 4.91 ± 0.16 0.40 ± 0.02
E PH/30 days/PB 6 0.21 ± 0.15 5.44 ± 0.22 0.49 ± 0.02 0.21 ± 0.01 5.04 ± 0.16 0.43 ± 0.02
F 30 days/PB 6 0.20 ± 0.15 5.44 ± 0.22 0.49 ± 0.02 0.19 ± 0.01 4.97 + 0.16 0.43 ± 0.02
G PH/PB 4 0.22 ± 0.18 5.83 ± 0.27 0.44 ± 0.03 0.22 ± 0.01 4.76 ± 0.20 0.45 ± 0.02
aValues are expressed as means ± standard error of the least-squares mean. Significant differences are not present between groups by
least-squares means comparisons (p S 0.05).
Table 6. TCA promotion organ/body weights.
Organ weight as % body weighta
3 months 6 months
Group Treatment N Spleen Liver Kidney Spleen Liver Kidney
M PH/DEN/PB 6 0.23 ± 0.01 5.47 ± 0.14* 0.53 ± 0.02 0.19 ± 0.13 5.06 ± 0.15* 0.42 ± 0.02
N PH/DEN/50 ppm TCA 6 0.23 ± 0.01 3.92 ± 0.14 0.52 ± 0.02 0.18 ± 0.13 3.76 ± 0.15 0.40 ± 0.02
O PH/DEN/500ppmTCA 6 0.20 ± 0.01 4.12 ± 0.14 0.55 ± 0.02 0.17 ± 0.13 4.41 ± 0.15 0.46 ± 0.02
P PH/DEN/5000 ppm 6 0.22 ± 0.01 4.25 ± 0.14 0.54 ± 0.02 0.19 ± 0.13 4.41 ± 0.15 0.48 ± 0.02
TCA
Q 5000 ppm 6 0.20 ± 0.01 4.19 ± 0.14 0.58 ± 0.02 0.18 ± 0.13 4.44 ± 0.15 0.53 ± 0.02
R PH 4 0.21 ± 0.02 3.73 ± 0.17 0.53 ± 0.02 0.18 ± 0.15 3.83 ± 0.19 0.46 ± 0.02
S PH/DEN 4 0.20 ± 0.02 3.90 ± 0.17 0.55 ± 0.02 0.15 ± 0.15 3.96 ± 0.19 0.49 ± 0.02
aValues are expressed as means ± standard error ofthe least-squares mean.
*Significantly greater than groups N, 0, P, Q, R, and S by least-squares means comparisons (p s 0.05). All other comparisons were not
significant.
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Table 7. TCA initiation GGT-positive foci.a
No. offoci/cm2
Group Treatment N 3 months 6 months
A PH/DEN/PB 6 2.05 ± 0.18* 9.93 ± 0.71*
B PH/1 dose/PB 6 0.05 ± 0.18 0.32 ± 0.71
C PH/10 days/PB 6 0.08 ± 0.18 0.28 ± 0.71
D PH/20 days/PB 6 0.07 + 0.18 0.30 ± 0.71
E PH/30 days/PB 6 0.06 + 0.18 0.33 ± 0.71
F /30 days/PB 6 0.10 ± 0.18 0.49 ± 0.71
G PH/PB 4 0.07 ± 0.22 0.14 ± 0.86
aValues are expressed as means ± standard error of the least-
squares mean.
*Significantly greater than groups B, C, D, E, F, and G by least-
squares means comparisons (p S 0.05). All other comparisons were
not significant.
ducers (31). No differences in body or organ weights
could be attributed to TCA administration. Addition-
ally, no necrosis was observed in the liver in anygroups
treated with TCA.
A significant (p < 0.05) increase in liver weight was
detected in the positive control (group M) of the pro-
motiongroups (Table 6). Thisincrease isconsistentwith
hepatomegaly because of microsomal induction com-
monly seen with PB treatment.
TCA Initiation
The results of the GGT-positive foci initiation bioas-
say are summarizedinTable 7. Onlythepositive control
(group A), which had approximately 2 and 10 foci/cm2
at 3 and 6 months, respectively, showed a statistically
significant effect. The initiation control (group G) had
almost no induction ofGGT-positive foci. These results
are consistent withthose ofotherinvestigators (41-43),
who have shown that both PH and PB promotion are
necessary to optimize the induction of DEN-initiated
enzyme-altered foci. The four TCA treatment groups
(B, C, D, and E) failed to demonstrate significant in-
duction of GGT-positive foci. The differences in size of
foci among the groups have not yet been statistically
evaluated.
TCA Promotion
The results of the promotion experiment are sum-
marized in Table 8. As with the initiation protocol re-
sults, the positive control (group M) had induced GGT-
positive foci at a level significantly (p < 0.05) higher
than that seen in the other groups at both the 3- and 6-
month intervals. The lack of significant foci induction
within the promotion controls (group S) or initiation/
promotion controls (group R) again supports the need
for both PH and PB promotion to optimize induction of
DEN-initiated foci. The low-dose (50 ppm) TCA-pro-
motion group (N) had significantly (p < 0.05) greater
foci induction at 3 months than any ofthe negative con-
trols (groups Q, R, and S), except for group R. This
same level offoci induction is seen with high-dose (5000
ppm) TCA promotion (group P). The statistical differ-
Table 8. TCA promotion GGT-positive foci.a
No. offoci/cm2
Group Treatment N 3 months 6 months
M PH/DEN/PB 6 1.65 ± 0.23* 7.61 ± 0.72*
N PH/DEN/50 ppm 6 0.71 ± 1.16t 1.83 ± 0.32t
TCA
O PH/DEN/500 ppm 6 0.39 + 0.16 1.63 ± 0.324:
TCA
P PH/DEN/5000 ppm 6 0.70 ± 0.16t 2.45 ± 0.324:
TCA
Q 5000 ppm TCA 6 0.23 ± 0.16 0.03 + 0.32
R PH 4 0.23 ± 0.20 0.41 ± 0.39
S PH/DEN 4 0.05 ± 0.20 0.30 ± 0.39
aValues are expressed as means ± standard error of the least-
squares mean.
*Significantly greater than groups N, 0, P, Q, R, and S by least-
squares means comparisons (ps 0.05).
tSignificantly greater than groups Q and S by least-squares means
comparisons (p
- 0.05). Group M excluded from comparisons.
tSignificantly greater than groups Q, R, and S by least-squares
means comparison (p E 0.05). Group M excluded from comparisons.
ences between the low and high TCA dose groups (N
and P) and control group R werep < 0.06 andp < 0.07,
respectively. The level of GGT-positive foci induction
seen at 3 months with 500 ppm TCA promotion (group
0) was greater than all the negative controls but was
not statistically significant. However, at the 6-month
interval, allthree dose levels ofTCApromotion (groups
N, 0, and P) resulted in statistically significant (p <
0.05) greater levels of foci induction compared to any
of the negative controls (groups Q, R, and S).
Discussion
It has been recently reported that TCA induces he-
patic peroxisomal enzyme activities (29,30). This per-
oxisomalstimulatingactivity, alongwithincreased met-
abolic TCA formation in the mouse compared to the rat
following TCE administration has led several research-
ers to speculate that TCA levels may be important for
explaining why TCE is carcinogenic in the mouse but
not in the rat (25,26).
In this study, when TCA was investigated for its
initiating potential in the rat hepatic foci bioassay, no
evidence of significant genotoxicity was found. Short-
terminvitro mutagenicity testing ofTCAhasalsobeen
negative (8,9). Although there appears to be little to
supportthenotionofsignificantgenotoxicTCAactivity,
the paucity of data does not allow a definitive deter-
mination at this time.
The promoting activity ofTCA was also investigated
using the rat hepatic system. After 3 months of TCA
administration in drinking water, significant, although
somewhat equivocal, promotion activity was observed
forboth the low dose (50ppm) and high dose (5000ppm)
ofTCA. The promoting activity associated withthe me-
diumdose ofTCA (500ppm), althoughresultinginmore
GGT-positive foci than those of the negative controls,
was not significant. However, by 6 months, all three
dose levels ofTCA produced significant increases in the
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number of GGT-positive foci. This promoting activity
was not, however, of the magnitude seen with pheno-
barbital, a known potent hepatic tumor promotor. No
dose-response relationship between the weak promot-
ing activity and the concentrations ofTCA used in this
study was evident.
Although TCA is reported to cause hepatic peroxi-
somal stimulation in rats and mice, the results of this
study indicate that it is unlikely that TCA's effects are
related to the promoting ability seen here. The minimal
stimulation, 10 to 20% over controls, of peroxisomal-
associated, cyanide-insensitive, palmitoyl-CoA oxida-
tionin TCA-exposed rats was seen only atthe 5000ppm
level and only within the promotion protocol. This find-
ing is in contrast to the promoting activity seen at all
three concentrations ofTCA. The lack ofhepatomegaly
associated with TCA administration is further evidence
ofTCA's weak ability to stimulate hepatic peroxisomes.
Known hepatic peroxisomal proliferators have been
shown to induce an associated hepatomegaly (40).
This study provides evidence that TCA is a possible
weak, epigenetic carcinogen. It should be pointed out
that no hepatocellular carcinomas or other hepatic tu-
mors were found in any of the experimental animals
used in this study. Further research is needed to verify
possible carcinogenic effects of TCA in other bioassay
systems.
This research was supported by U.S. Environmental Protection
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